Approved in 2011 by the FDA, Xeomin is a “naked” neurotoxin. That is, Xeomin contains only a single ingredient (botulinum toxin type A), while the formulation of Botox and Dysport contains various protective proteins clustered around the active molecule. The benefit of Xeomin’s pure-form means users have a lower chance of developing resistance (antibodies) that can limit its desired effects, so it is a good option for people who didn’t respond well to other neuromodulator treatments. Xeomin treatment can be completed within 15 minutes for most patients.